Form 8-K - Current report:
SEC Accession No. 0001213900-25-027106
Filing Date
2025-04-01
Accepted
2025-04-01 16:02:31
Documents
14
Period of Report
2025-04-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0236644-8k_inmune.htm   iXBRL 8-K 23297
2 PRESS RELEASE DATED APRIL 1, 2025 ea023664401ex99-1_inmune.htm EX-99.1 12537
  Complete submission text file 0001213900-25-027106.txt   213713

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20250401.xsd EX-101.SCH 3017
4 XBRL LABEL FILE inmb-20250401_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE inmb-20250401_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0236644-8k_inmune_htm.xml XML 3679
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 25799538
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)